- Home
- PPL vs ONC Comparison
PPL vs ONC Comparison
Compare PPL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPL | ONC |
|---|---|---|
| Founded | 1920 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 34.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PPL | ONC |
|---|---|---|
| Price | $33.95 | $319.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $40.10 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 7.8M | 279.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 32.44 | N/A |
| EPS | ★ 1.47 | 0.58 |
| Revenue | ★ $8,979,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $7.55 | $895.40 |
| Revenue Next Year | $5.11 | $22.04 |
| P/E Ratio | ★ $23.12 | $514.97 |
| Revenue Growth | 8.42 | ★ 50.43 |
| 52 Week Low | $31.22 | $170.99 |
| 52 Week High | $38.27 | $385.22 |
Technical Indicators
Market Signals| Indicator | PPL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 41.76 |
| Support Level | $33.17 | $315.50 |
| Resistance Level | $34.24 | $326.77 |
| Average True Range (ATR) | 0.57 | 11.23 |
| MACD | -0.19 | -3.05 |
| Stochastic Oscillator | 21.76 | 18.85 |
Price Performance
Historical ComparisonAbout PPL PPL Corporation
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.